|
業務類別
|
Biotechnology |
|
業務概覽
|
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World. |
| 公司地址
| 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070 |
| 電話號碼
| +1 650 260-7120 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.iovance.com |
| 員工數量
| 975 |
| Dr. Igor P. Bilinsky, PhD |
Chief Operating Officer |
美元 570.53K |
28/04/2026 |
| Mr. Daniel Gordon Kirby |
Chief Commercial Officer |
美元 507.53K |
28/04/2026 |
| Dr. Frederick G. Vogt, J.D. |
Director, General Counsel, Interim Chief Executive Officer and President |
美元 800.00K |
28/04/2026 |
| Ms. Corleen M. Roche |
Chief Financial Officer and Principal Accounting Officer |
美元 243.29K |
28/04/2026 |
| Dr. Friedrich Graf Finckenstein, M.D. |
Chief Medical Officer |
-- |
28/04/2026 |
| Dr. Raj K. Puri, M.D.,PhD |
Chief Regulatory Officer |
美元 671.94K |
28/04/2026 |
|
|
| Dr. Michael Weiser,M.D.,PhD |
Independent Director |
28/04/2026 |
| Mr. Ryan D. Maynard |
Independent Director |
28/04/2026 |
| Dr. Athena Countouriotis, M.D. |
Independent Director |
28/04/2026 |
| Mr. Wayne P. Rothbaum |
Independent Director |
28/04/2026 |
| Dr. Iain D. Dukes, D.Phil. |
Chairman of the Board |
28/04/2026 |
| Dr. Frederick G. Vogt, J.D. |
Director, General Counsel, Interim Chief Executive Officer and President |
28/04/2026 |
| Ms. Wendy L. Yarno, M.B.A. |
Independent Director |
20/03/2026 |
|
|
|
|
